DGAP-News: MOLOGEN AG: Early departure of CEO

PRESS RELEASE N° 5 / 2019 of 03/18/2019 

MOLOGEN AG: Early departure of CEO

Berlin, 18 March 2019 - The biopharmaceutical company MOLOGEN AG (ISIN DE000A2LQ900, SIN A2L Q90) (MOLOGEN or the Company) announced yesterday that the Chief Executive Officer (CEO) of the Company, Dr Ignacio Faus, will depart from his post as Chairman and member of the Executive Board early, with effect from 31 March 2019 by mutual agreement with the Supervisory Board. Until he leaves MOLOGEN AG, Dr Faus will continue to be responsible for the Company's business.

"I am grateful for the good time at MOLOGEN, especially with regard to the development of our main product lefitolimod, which is currently in the IMPALA phase III pivotal clinical trial. This is all the more exciting as we expect top-line data for this study to be available in the second half of the year. I am sure MOLOGEN will move forward against and despite the background of the challenges our Company is currently facing, especially the disputes amongst some of the shareholders," said Dr Ignacio Faus, CEO of MOLOGEN.

The Supervisory Board thanks Dr Faus for his commitment and achievements and wishes him all the best for the future.

The Supervisory Board of the Company will decide on the successor shortly.
MOLOGEN AG
MOLOGEN AG is a biopharmaceutical Company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.
The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead compound lefitolimod and the next-generation molecule family EnanDIM^(R).

The immunotherapeutic agent lefitolimod is the Company's lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in extensive-stage small cell lung cancer (ES-SCLC) and the data from the extension phase of the TEACH study in HIV have been published. In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy^(R)) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.

MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange.

www.mologen.com
Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com
Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.